1
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang, ALEXANDER John B, January 27, 2005: WO/2005/007648 (17 worldwide citation)

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with path ...


2
Toufike Kanouni
Qing Dong, Toufike Kanouni, John David Lawson, Michael B Wallace: Dihydropyrrolonaphtyridinone compounds as inhibitors of jak. Takeda Pharmaceutical Company, June 9, 2011: US20110136780-A1

Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the ...


3
Gagan Kukreja
Venkata P Palle, Sarala Balachandran, Mohammad Salman, Gagan Kukreja, Nidhi Gupta, Abhijit Ray, Sunanda G Dastidar: Inhibitors of phosphodiesterase type-IV. Ranbaxy Laboratories, November 2, 2010: US07825147

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psori ...


4
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


6
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Jeffrey H Tidwell, Stephen D Prodnuk, Vincent P Liptak, December 28, 2010: US07858643 (6 worldwide citation)

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


7
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, October 18, 2012: US20120263706-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


8
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Pfizer, December 23, 2010: US20100324061-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.


9
Prabhu Mohapatra
Laxminarayan Bhat, Prabhu P Mohapatra, Seema Rani Bhat: Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents. Reviva Pharmaceuticals, Fenwick & West, November 27, 2008: US20080293736-A1

The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.


10
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, Agouron Pharmaceuticals, June 15, 2006: US20060128724-A1

Compounds of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.